{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,5,14]],"date-time":"2025-05-14T09:12:43Z","timestamp":1747213963618,"version":"3.40.5"},"posted":{"date-parts":[[2021,6,12]]},"group-title":"Open Science Framework","reference-count":0,"publisher":"Center for Open Science","license":[{"start":{"date-parts":[[2021,6,12]],"date-time":"2021-06-12T00:00:00Z","timestamp":1623456000000},"content-version":"unspecified","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/legalcode"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"abstract":"<p>As biomedicine progresses, more laboratories are moving their attention to clinical research, and a significant breakthrough has been made in the treatment of multiple sclerosis (MS). Modern disease therapy, on the other hand, is primarily concerned with alleviating clinical symptoms and, where possible, improving function. Patients with MS are more likely to develop depression, cognitive and behavioral issues, and possibly permanent disability as the disease progresses.There is no doubt that the current treatment strategy is insufficient. We require a more ambitious strategy that incorporates a variety of therapies in order to maximize synergy. It is possible that a combination of symptomatic medicines (such as those for cramps, fatigue and depression), rehabilitation, and specific MS treatments will give the best chance of halting the course of MS in some people. Such research, on the other hand, would be time-consuming, expensive, and challenging.<\/p>","DOI":"10.31219\/osf.io\/sycn6","type":"posted-content","created":{"date-parts":[[2021,6,12]],"date-time":"2021-06-12T12:56:07Z","timestamp":1623502567000},"source":"Crossref","is-referenced-by-count":1,"title":["Strategies for treating multiple sclerosis with gene therapy"],"prefix":"10.31219","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-6189-3020","authenticated-orcid":true,"given":"Moataz","family":"Dowaidar","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"15934","container-title":[],"original-title":[],"deposited":{"date-parts":[[2021,6,12]],"date-time":"2021-06-12T12:56:08Z","timestamp":1623502568000},"score":1,"resource":{"primary":{"URL":"https:\/\/osf.io\/sycn6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,6,12]]},"references-count":0,"URL":"https:\/\/doi.org\/10.31219\/osf.io\/sycn6","relation":{},"subject":[],"published":{"date-parts":[[2021,6,12]]},"subtype":"preprint"}}